- Datum17.12.2026
- Uhrzeit17:00 - 17:30 Uhr
- Veranstalter
stock3
Athira Pharma Inc. Chart inkl. Chartanalyse

Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen

Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Société Générale | VK | |||||
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Wertentwicklung (Nasdaq)
Passender Service zu Athira Pharma Inc.
Webinar zu Athira Pharma Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,910-14,210
- Jahrestief / Hoch ($)1,910-14,210
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Athira Pharma Inc.
Termine von Athira Pharma Inc.
Beschreibung
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
